Fierce Pharma

JANUARY 29, 2024

The start of the new year doesn’t seem to have dulled the zeal of Pfizer’s global cost-cutting campaign, which has already left hundreds of jobs in its wake. | Come mid-February, Pfizer will lay off some 52 employees at a facility in South San Francisco, according to a recent Worker Adjustment and Retraining Notification Act alert. The site is the former headquarters of Global Blood Therapeutics.

334

334

MedCity News

JANUARY 31, 2024

We and our collective organizations’ providers have treated 10,000’s of Americans, who suffer from obesity and/or Type 2 diabetes with GLP-1 drugs. And we believe we have important observations to share.

Biopharma 143

Biopharma 143

Pharmaceutical Technology

JANUARY 29, 2024

At the JP Morgan Healthcare conference, Merck (MSD) indicated its eagerness to continue to establish its place in the immunological space.

Healthcare 144

Healthcare Healthcare 144

Pharmaceutical Commerce

FEBRUARY 2, 2024

A dive into this market reveals that the latest numbers yield promising results—a global value of a worldwide $1.6 trillion—but it will continue to be attributed to past, present, and future healthcare spending.

Prescription 116

Prescription Sales Healthcare Healthcare 116

Advertisement

Distribution

Fierce Pharma

JANUARY 31, 2024

More than two years after Aduhelm's controversial and ill-fated FDA accelerated approval, Bi | Biogen is discontinuing its first Alzheimer's disease therapy, Aduhelm, after walking a rocky path. The company is taking a $60 million charge, halting sales and terminating a confirmatory trial.

FDA 310

FDA Sales 310

MedCity News

JANUARY 28, 2024

As the food as medicine movement grows, some payers and healthcare organizations are carving out specific roles and teams dedicated to food and nutrition. Doing so can be beneficial considering the significant impact diet can have on health outcomes.

Food 132

Food Medicine Healthcare Healthcare 132

Pharmaceutical Commerce

JANUARY 29, 2024

In an interview with Pharma Commerce Associate Editor Don Tracy, Ron Lanton, Partner, Lanton Law PLLC, discusses recent moves by CVS and Express Scripts to follow Mark Cuban's drug plus model.

Pharma 110

Pharma 110

Fierce Pharma

FEBRUARY 2, 2024

Mark your calendars, oncology drug and CAR-T therapy developers. | Mark your calendars, oncology drug and CAR-T therapy developers. The FDA has decided on a date for a highly anticipated advisory committee meeting for Bristol Myers' Abecma and J&J's Carvykti.

FDA 301

FDA 301

MedCity News

JANUARY 30, 2024

Even just a year ago, we couldn’t fathom a cure for cancer. Now, we can. Artificial intelligence (AI) is rapidly transforming the healthcare industry, with its ability to process and analyze vast amounts of data. Cancer treatment is one area that could benefit significantly from AI, as it can aid in early detection, precise diagnosis, and personalized treatment plans.

Side effects 125

Side effects Ethics Medical Patients 125

Integrity Solutions

FEBRUARY 1, 2024

Is sales still a viable profession today? Is it something needed or that people even want to do? Many who are currently in sales positions or are considering a role in sales are beginning to question what the job really means today and whether it’s one they can be proud of — especially when it feels like their whole purpose can feel like it’s to pressure or coerce buyers into doing something.

Sales 106

Sales Training B2B Sales Sales process 106

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

pharmaphorum

FEBRUARY 1, 2024

A phase 2 trial of Lundbeck’s alpha-synuclein-targeting drug Lu AF82422 has failed to reach statistical significance in patients with multiple system atrophy (MSA), although the company says there are encouraging “signals of efficacy” in the data.

Patients 103

Patients 103

Fierce Pharma

JANUARY 31, 2024

Beaten to the punch by Pfizer in developing a vaccine for COVID, GSK has regained some of its lost luster as a vaccine powerhouse with its advancement of respiratory syncytial virus (RSV) shot Arex | GSK's RSV vaccine Arexvy generated $1.5 billion in sales in 2023 compared to $890 million for Pfizer's Abrysvo. But the British pharma major says that the successful launch represents just one round of a boxing match, and much is still to be decided, especially with Moderna expected to joi

Pharma 297

Pharma Sales 297

MedCity News

FEBRUARY 2, 2024

A new era in maternal care is emerging with the advent of maternity care management platforms. Innovative organizations are centralizing the coordination of all patient care aspects, seamlessly integrating with providers’ electronic health records, existing workflows, and health information exchanges.

Networking 119

Networking Electronics Management Patients 119

Pharmaceutical Technology

JANUARY 29, 2024

The rapid sequencing of the SARS-CoV-2 and the subsequent development of mRNA vaccines led to the authorisation of the first of these vaccines in late 2020.

Leads 111

Leads 111

Advertiser: ZoomInfo

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

Competition

pharmaphorum

JANUARY 31, 2024

Novartis ends development of Tim3 antibody sabatolimab in myelodysplastic syndromes after failed phase 3 trial.

126

126

Fierce Pharma

JANUARY 29, 2024

New legislation aimed at blocking a group of Chinese biopharma firms from tapping into U.S. federal funding has sent shares tumbling in recent days. | New legislation aimed at blocking a group of Chinese biopharma firms from tapping into U.S. federal funding has sent shares tumbling in recent days. WuXi Bio, for its part, says it's not affiliated with the military in China.

Biopharma 291

Biopharma 291

MedCity News

FEBRUARY 2, 2024

Alto Neuroscience will apply the IPO proceeds toward clinical tests of its psychiatric drugs in patients who exhibit certain biomarkers. The company’s two most advanced programs are depression drugs in mid-stage development.

Patients 118

Patients Biopharma Pharma 118

Copyright Clearance Center

FEBRUARY 1, 2024

February 1, 20 24 – Danvers, Mass. – CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, announces that its President and CEO, Tracey Armstrong , was named a winner of the 2024 BIG Innovation Award recognizing organizations, products, and people bringing new ideas to life in innovative ways and presented by Business Intelligence Group.

Leads 98

Leads Management 98

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

PharmaTech

JANUARY 31, 2024

This article introduces that the basic technique for tolerance interval is implemented using the conventional range 85–115% LC where the proposed range in the PF is not taken into account.

98

98

Fierce Pharma

FEBRUARY 1, 2024

With Merck reporting a whopping $25 billion sales haul for | With Merck reporting a whopping $25 billion sales haul for Keytruda on Thursday, the PD-1 cancer superstar appears to be the world’s top-selling drug in 2023. Keytruda looks set to take over the top spot from Pfizer and BioNTech’s Comirnaty, which ruled the previous two years, scoring sales of $55.9 billion in 2022 and $55.1 billion in 2021.

Sales 285

Sales 285

MedCity News

FEBRUARY 1, 2024

Despite Cigna and Humana ditching their pursuits to combine in December, one industry expert believes there’s still a chance after Cigna announced its plan to sell its Medicare Advantage business to Health Care Service Corp.

Sales 118

Sales 118

pharmaphorum

JANUARY 29, 2024

Spanish drugmaker Grifols has hit back at hedge fund Gotham City Research, which claimed it had fraudulently manipulated its financial reporting, with a lawsuit filed in New York. The complaint has been brought against Gotham City and co-founders Daniel Yu and Cyrus de Weck, along with other defendants, and accuses them of being “predatory short sellers…who illicitly profit from their rigged short-and-distort schemes.

97

97

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Distribution

European Pharmaceutical Review

JANUARY 29, 2024

N-Nitrosamines By far the biggest issue bedevilling industry during 2023 was the continuing N-nitrosamine contamination saga, which was covered in the third issue of EPR 2023. 1 Some five years after the initial NDMA (N-nitrosodimethylamine) contamination issue 2 initially affecting valsartan drug substance, then other active pharmaceutical ingredients (APIs), eg, sartans, ranitidine, metformin, etc; the toxic short alkyl chain N-nitrosamine issue appears, if not resolved, then well on the way t

Pharmaceutical 98

Pharmaceutical Food and Drug Administration Medicine FDA 98

Fierce Pharma

FEBRUARY 1, 2024

Even after the acquisitions of Prometheus and Acceleron, Merck is ready to make more deals in the $1 to $15 billion range, according to CEO Rob Davis.

Marketing 291

Marketing 291

MedCity News

JANUARY 28, 2024

While pharmaceutical companies continue to raise list prices year-over-year, we work behind the scenes to fight the trend by driving competition, negotiating with drugmakers and incentivizing the use of less expensive medicines that deliver the same clinical value.

Competition 119

Competition Medicine Pharma Patients 119

pharmaphorum

JANUARY 30, 2024

From today, a new feature added to the NHS App used in the UK will allow millions of people to submit and view prescriptions, in a bid to save time for patients and doctors. The digital prescription function, which does away with the need for paper scrip, was put through its paces in a pilot trial last year involving a million users of the app, now being used by three-quarters of the UK population or around 33.5 million people.

Prescription 97

Prescription Doctors Patients 97

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Safety

Impetus Digital

FEBRUARY 1, 2024

Register for one of Impetus’ upcoming webinars between February 26-28: Top-5 Trends in Virtual KOL Engagement About the webinar We’re taking a look at the top trends from 2023 and share our predictions for the new year. Our expert speakers will share their unique industry insights and the “best of the best” virtual collaboration and insight-gathering programs from 2023.

Professional Services 97

Professional Services Education Healthcare Provider Patients 97

Fierce Pharma

FEBRUARY 1, 2024

Despite litigation and denouncements from the biopharma industry, Medicare price negotiations under the Inflation Reduction Act are rolling on. | Despite litigation and denouncements from the biopharma industry, Medicare price negotiations under the Inflation Reduction Act are rolling on. And today, the government is sending out its first round of offers on affected drugs.

Biopharma 256

Biopharma Government 256

MedCity News

JANUARY 29, 2024

Science 37 rode the trends of Covid-19 technologies and SPAC mergers to a more than $1 billion valuation. But revenue for the decentralized clinical trials software firm stopped growing, and it’s now going private valued at just $38 million.

Biopharma 116

Biopharma Pharma 116

pharmaphorum

JANUARY 30, 2024

Legislation filed in the US is seeking to block Chinese biotech companies from federal contracts on the grounds they are a national security concern

107

107

Advertiser: ZoomInfo

In times of economic uncertainty, account-based strategies are essential. According to several business analysts and practitioners, ABM is a necessity for creating more predictable revenue. Research shows that nearly three-quarters of marketers (74%) already have the resources needed to build successful ABM programs.

Marketing